Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRX34
- Development stage
- Discontinued
- Lead developer
- Synlogic
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
MRX34 is a liposomal miR-34a mimic, representing a potential first-in-class microRNA therapy for cancer. It delivers the naturally occurring tumor suppressor miR-34a, which down-regulates expression of more than 30 oncogenes and genes involved in tumor immune evasion (e.g., PD-L1). The drug showed dose-dependent repression of miR-34a target oncogenes including FOXP1, BCL2, HDAC1, and CTNNB1 in clinical trials.
- Other names
- MIR-34MIR34MIR 34MIR-34 MIMICMIR34 MIMICMIR 34 MIMIC
02
Targets
MicroRNA-34a response element-containing oncogene messenger RNAs
Beyond the preview
Go deeper on MRX34.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRX34.